On August 24, 2026, the Office of the Secretary of the U.S. Department of Health and Human Services (HHS) officially published a Request for Information (RFI) in the Federal Register titled "Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making" (FR Doc. 2026-17250; 91 FR 54724–54728; Docket No. HHS-OS-2026-0332; RIN 0991-ZA62).
The notice follows an HHS press release dated August 21, 2026, which announced the agency's intent to solicit public feedback on whether the current tripartite structure of federal immunization guidance—routine (universal), risk-based (targeted), and shared clinical decision-making (SCDM, also described by the agency as individual-based decision-making)—remains appropriate. The RFI explicitly cites the Executive Order of August 10, 2026 regarding gold-standard childhood vaccine recommendations and the newly established Task Force on Safer Childhood Vaccines. Public comments on the docket are due within a compressed 27-day window, closing on September 20, 2026.
For vaccine manufacturers, commercial payers, state Medicaid directors, Vaccines for Children (VFC) coordinators, and healthcare providers, the immediate operational and financial question is clear:
If HHS or the CDC alters federal vaccine recommendation categories—or shifts an immunization from a routine recommendation to shared clinical decision-making—does zero-cost-sharing coverage under Section 2713 of the Affordable Care Act (ACA), Vaccines for Children (VFC) entitlement, or Medicare Part B preventive coverage automatically fall away?
The direct regulatory answer is no, not automatically, and certainly not from this RFI alone.
The August 24 publication is a formal inquiry, not an administrative schedule revision, a final rulemaking, or an immunization schedule recategorization. More crucially, in Question 12 of the RFI itself, HHS acknowledges a statutory and regulatory reality that many public commentaries overlook: under current law and federal regulations, an SCDM recommendation, once formally adopted by the Director of the Centers for Disease Control and Prevention (CDC), triggers the exact same statutory coverage requirements as a routine universal recommendation, including first-dollar commercial coverage without cost-sharing under ACA § 2713 and guaranteed availability through the federal VFC program.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ HHS VACCINE-CATEGORY RFI: STATUTORY & REGULATORY SNAPSHOT │
├─────────────────────────────────────┬────────────────────────────────────────────────────────┤
│ Parameter │ Published Regulatory Specification │
├─────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ Federal Register Notice │ FR Doc. 2026-17250; 91 FR 54724–54728 (5 pages) │
│ Docket & RIN Numbers │ Docket No. HHS-OS-2026-0332; RIN 0991-ZA62 │
│ Press Release Date │ August 21, 2026 (Washington, D.C.) │
│ Official FR Publication Date │ August 24, 2026 │
│ Public Comment Deadline │ September 20, 2026 (27-day comment window) │
│ Issuing Office │ Office of the Secretary (HHS OS) │
│ Enabling Authority & Precedent │ EO of August 10, 2026; Task Force on Safer Vaccines │
│ Core Statutory Clock Intersect │ PHS Act § 2713 (42 U.S.C. 300gg-13) & 45 CFR 147.130 │
│ Public Entitlement Intersect │ PHS Act § 1928 / Social Security Act § 1928 (VFC) │
│ Current Judicial Injunction Status │ AAP v. Kennedy (Mar 16, 2026 injunction stays ACIP) │
└─────────────────────────────────────┴────────────────────────────────────────────────────────┘
Below, we dissect the administrative anatomy of the August 24 RFI, map the statutory coverage mechanics connecting Advisory Committee on Immunization Practices (ACIP) categories to commercial and public reimbursement, analyze the critical prompts in Questions 6 and 12, reconcile the stale five-recommendation CDC FAQ against recent schedule footnotes, and examine why this RFI cannot unfreeze the stalled ACIP machinery.
What HHS Actually Published on August 24
The August 24 RFI is structured around three foundational categories currently employed by the federal government when issuing clinical immunization guidance:
- Routine (Universal) Recommendations: Broad, default recommendations applicable to all individuals within a designated age cohort (e.g., standard pediatric MMR, DTaP, or annual influenza vaccination). The clinical default is to administer the vaccine unless a specific medical contraindication exists.
- Risk-Based (Targeted) Recommendations: Recommendations tailored to specific sub-populations defined by underlying clinical conditions, immunocompromised status, anatomical risk factors, occupational exposures, travel, or outbreak settings (e.g., pneumococcal conjugate schedules in chronic renal failure or asplenia).
- Shared Clinical Decision-Making (SCDM / Individual-Based): Recommendations where there is no universal default to vaccinate. Instead, the administration of the vaccine depends on an individualized clinical discussion between the patient (or parent/guardian) and the healthcare provider, weighing the individual's specific risk of disease, personal values, and the vaccine's protective characteristics (e.g., meningococcal B vaccination for adolescents aged 16–23 who are not at elevated risk).
HHS's notice explains that while the three-category system has evolved over decades of ACIP deliberative practice, the agency seeks public input on whether these definitions create clinical ambiguity, whether providers understand the operational implications of SCDM, and whether a redesigned taxonomy would improve clinical clarity or patient autonomy.
The August 21 Press Date vs. The August 24 Federal Register Publication
A common point of administrative confusion in trade commentary stems from the date gap between HHS's press room announcement on Friday, August 21, 2026, and the official publication of Document 2026-17250 in the Federal Register on Monday, August 24, 2026.
Under the Administrative Procedure Act (APA; 5 U.S.C. 551 et seq.) and Federal Register formatting rules, legal comment clocks begin on the date of publication in the printed Federal Register. Thus, the 27-day public comment window closes on September 20, 2026. Submissions must be routed to Docket No. HHS-OS-2026-0332 via the Federal eRulemaking Portal at Regulations.gov.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ THREE-TIER IMMUNIZATION TAXONOMY: CLINICAL & COVERAGE MATRIX │
├──────────────────────┬─────────────────────────────┬─────────────────────────────────────────┤
│ Category │ Clinical Default & Intent │ Mandatory Coverage Treatment │
├──────────────────────┼─────────────────────────────┼─────────────────────────────────────────┤
│ Routine (Universal) │ • Default decision to │ • First-dollar ACA § 2713 coverage. │
│ │ vaccinate everyone in age │ • Full VFC entitlement for eligible. │
│ │ or population cohort. │ • Medicare Part B preventive (statute). │
│ │ • Opt-out requires contra- │ • State school immunization mandate │
│ │ indication or exemption. │ frequently links to routine list. │
├──────────────────────┼─────────────────────────────┼─────────────────────────────────────────┤
│ Risk-Based (Targeted)│ • Default to vaccinate when │ • First-dollar ACA § 2713 coverage │
│ │ clinical, anatomical, or │ for patients meeting risk criteria. │
│ │ environmental risk met. │ • VFC entitlement for at-risk children. │
│ │ • Requires clinical triage. │ • Medicare Part B/D based on risk. │
├──────────────────────┼─────────────────────────────┼─────────────────────────────────────────┤
│ Shared Clinical │ • NO default to vaccinate. │ • FULL first-dollar ACA § 2713 coverage │
│ Decision-Making │ • Individualized risk/ │ when listed on CDC schedule (FAQ/Q12).│
│ (SCDM / Individual) │ benefit discussion. │ • Full VFC availability (no copay). │
│ │ • Provider-patient decision.│ • Plans MAY NOT impose cost-sharing. │
└──────────────────────┴─────────────────────────────┴─────────────────────────────────────────┘
Do Category Changes Automatically Alter ACA 2713, VFC, and Medicare Clocks?
The core misunderstanding driving much of the current debate is the assumption that shifting a vaccine from "routine" to "shared clinical decision-making" converts the product into an optional, uncovered, out-of-pocket medical expense.
To understand why this is legally incorrect under current law, one must examine the governing statutes and regulations.
1. Affordable Care Act Section 2713 and 45 CFR 147.130
Section 2713 of the Public Health Service Act (PHS Act; 42 U.S.C. 300gg-13), as added by the ACA, mandates that non-grandfathered group health plans and health insurance issuers offering group or individual health insurance coverage must provide coverage for, and must not impose any cost-sharing requirements (such as copayments, coinsurance, or deductibles) for:
"immunizations that have in effect a recommendation from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention with respect to the individual involved."
The joint implementing regulations—codified for HHS at 45 CFR 147.130, for the Department of Labor at 29 CFR 2590.715-2713, and for the Department of the Treasury at 26 CFR 54.9815-2713—establish the operational coverage clock:
- A recommendation is considered "in effect" after it has been formally adopted by the Director of the CDC.
- A recommendation is considered to be for "routine use" if it is listed on the Official Immunization Schedules published by the CDC (including child, adolescent, and adult schedules).
- Plans and issuers must implement coverage for a newly adopted recommendation starting with the first plan year (or policy year) that begins on or after the date that is one year after the recommendation is issued.
Crucially, 45 CFR 147.130 does not distinguish between a routine universal recommendation and an SCDM recommendation, provided that the SCDM recommendation is adopted by the CDC Director and incorporated into the CDC immunization schedule. If an individual in the covered population elects to receive the vaccine following a clinical discussion, the commercial health plan is legally prohibited from charging a copay or applying a deductible.
2. The Vaccines for Children (VFC) Program Entitlement
Under Section 1928 of the Social Security Act (42 U.S.C. § 1396s), the Vaccines for Children program provides federally purchased pediatric vaccines at no cost to eligible children (Medicaid-eligible, uninsured, underinsured, and American Indian/Alaska Native children).
The VFC program is legally bound to the resolutions passed by ACIP and adopted by the CDC Director. When ACIP issues an SCDM resolution for a pediatric or adolescent indication and incorporates it into the VFC resolution framework, participating VFC providers are entitled to order the vaccine through public inventory, and no administration fee or product cost may be levied against the family.
3. Medicare Part B Preventive Immunization
Medicare Part B covers specific preventive immunizations (influenza, pneumococcal, hepatitis B for intermediate/high risk, and COVID-19) under explicit statutory benefit categories (Section 1861(s)(10) of the Social Security Act; 42 U.S.C. § 1395x(s)(10)) with statutory zero coinsurance and deductible exemptions under Section 1833. Other adult commercial vaccines are covered under Medicare Part D, where the Inflation Reduction Act of 2022 eliminated Part D vaccine cost-sharing for all ACIP-recommended adult vaccines.
Dissecting RFI Questions 6 and 12: The Policy Core
The most revealing elements of the August 24 Federal Register notice are found in the specific numbered prompts that HHS put forward for stakeholder feedback. Rather than a superficial inquiry, the notice directly confronts the friction between clinical nuance and statutory reimbursement.
Question 12: The Statutory Coverage-Equivalence Concession
In Question 12 of the notice, HHS states:
"An SCDM recommendation, once adopted by the CDC Director, triggers the same coverage requirements as a routine recommendation, including coverage without cost-sharing under the Affordable Care Act and availability through the Vaccines for Children program. Given evidence that patients and even providers may not understand this, what steps should the Department take to educate the public and the provider community that SCDM-recommended vaccines are covered? What communication formats would most effectively ensure that an SCDM designation is not misread as a lapse in coverage or a signal that a vaccine is unavailable?"
This question is a critical regulatory concession. It confirms that the Office of the Secretary recognizes that SCDM is not an exclusion from coverage. However, it also highlights an acute operational failure: in practice, when commercial payers, billing clearinghouses, or utilization management algorithms see "shared decision-making," they frequently misunderstand the category as "optional lifestyle" or "investigational," leading to improper claim rejections or cost-sharing assessments that violate 45 CFR 147.130.
Question 6: Downstream Interlocks with Programs, Compensation, and State Law
In Question 6, HHS asks, if new categories were adopted, what would be needed "to preserve access to vaccines currently available to Americans and ensure predictable and consistent treatment under coverage requirements, program eligibility rules, the injury-compensation programs, and State law." That prompt does not name ACA § 2713, VFC, VICP, or school-entry statutes, but those are the coverage, eligibility, compensation, and state-law clocks the question puts in play:
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ HHS RFI QUESTION 6: DOWNSTREAM IMPACT INTERLOCKS │
├────────────────────────────┬─────────────────────────────────────────────────────────────────┤
│ Interlock Domain │ Statutory / Operational Friction Point │
├────────────────────────────┼─────────────────────────────────────────────────────────────────┤
│ 1. ACA Section 2713 │ 45 CFR 147.130 requires "routine use" on CDC schedule. If a │
│ Private Insurance │ new category is created (e.g. "conditional"), does 147.130 apply│
│ │ without an APA notice-and-comment regulatory amendment? │
├────────────────────────────┼─────────────────────────────────────────────────────────────────┤
│ 2. Vaccines for Children │ SSA § 1928 ties VFC purchasing to ACIP resolutions. Category │
│ (VFC) Program │ restructuring could create supply contracting misalignments. │
├────────────────────────────┼─────────────────────────────────────────────────────────────────┤
│ 3. Vaccine Injury │ VICP covers vaccines recommended by CDC for routine │
│ Compensation (VICP) │ administration to children/pregnant women, subject to excise │
│ │ tax. Shifting categories risks litigation over VICP vs tort. │
├────────────────────────────┼─────────────────────────────────────────────────────────────────┤
│ 4. State School Laws │ State statutes often cross-reference "ACIP routine pediatric │
│ & Local Mandates │ schedule." Altering federal category names disrupts state codes.│
└────────────────────────────┴─────────────────────────────────────────────────────────────────┘
Question 6 demonstrates that HHS is acutely aware of the administrative domino effect. If HHS or CDC renames categories without amending 45 CFR 147.130, health insurers could litigate whether a newly labeled category triggers mandatory coverage. Furthermore, because the National Vaccine Injury Compensation Program (VICP; 42 U.S.C. § 300aa-10 et seq.) relies on congressional excise taxes and specific CDC routine recommendations for children and pregnant women, altering category definitions threatens to disrupt the liability shield and compensation structure established by the National Childhood Vaccine Injury Act of 1986.
The CDC SCDM FAQ vs. 2025–2026 Schedule Footnotes
A major source of analytical error in recent trade commentary is reliance on outdated agency web pages. As of August 24, 2026, the official CDC web resource titled "ACIP Shared Clinical Decision-Making Recommendations" continues to state:
"ACIP has five recommendations for vaccination based on shared clinical decision-making."
That FAQ page, as extracted on August 24, 2026, states the five-recommendation count and explains that SCDM items have no default decision to vaccinate. It does not enumerate the five products in a single list. CDC job aids linked from the same page address meningococcal B vaccination, HPV vaccination for adults aged 27–45 years, pneumococcal vaccination for older adults, hepatitis B vaccination, and additional COVID-19 doses for people who are moderately or severely immunocompromised. Those job aids are the place to identify current SCDM products—not a reconstructed list treated as if it appeared on the FAQ itself. Schedule footnotes, not the FAQ count, are what 45 CFR 147.130 coverage attaches to.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ CDC SCDM FAQ VS. 2025–2026 SCHEDULE EVOLUTION │
├────────────────────────────────┬─────────────────────────────────────────────────────────────┤
│ Dimension │ Regulatory Reality & Analytical Lag │
├────────────────────────────────┼─────────────────────────────────────────────────────────────┤
│ CDC FAQ Text (as of 08/24/2026)│ States ACIP has "five recommendations" based on SCDM. │
│ Schedule Footnote Reality │ 2025–2026 adult and child schedule footnotes use subtle │
│ │ variations ("individual clinical decision," "may receive"). │
│ Regulatory Lag Risk │ FAQ pages are static web assets; schedule footnotes govern │
│ │ actual clinical guidance and 45 CFR 147.130 enforcement. │
│ Operational Impact │ Payer clearinghouses hardcoding the "five" miss newer │
│ │ schedule-level individual-based recommendations. │
└────────────────────────────────┴─────────────────────────────────────────────────────────────┘
The Analytical Disconnect
While the CDC FAQ text maintains the "five recommendations" count, the published 2025–2026 Child and Adolescent and Adult Immunization Schedules contain nuanced footnote language regarding respiratory syncytial virus (RSV) in specific adult cohorts, expanded pneumococcal conjugate choices, and COVID-19 interval adjustments that blur the boundary between strict risk-based guidance and individual clinical decision-making.
For market access teams, tracking the actual CDC schedule footnotes—rather than static educational FAQs—is paramount. Under 45 CFR 147.130, health plan coverage mandates attach to what is adopted by the CDC Director and published in the official schedules, not to auxiliary FAQ overviews.
Why This RFI Does Not Unfreeze ACIP
To accurately evaluate the commercial environment, industry analysts must separate HHS Office of the Secretary policy initiatives from the operational status of ACIP itself.
As previously detailed in our coverage of the mFlusiva frozen-ACIP coverage clocks, the federal immunization recommendation pathway has been under severe administrative disruption since early 2026.
The AAP v. Kennedy Preliminary Injunction
On March 16, 2026, U.S. District Judge Brian Murphy issued a preliminary injunction in American Academy of Pediatrics v. Kennedy (D. Mass., Civil Action No. 26-cv-10412), the same order already discussed on this site in the mFlusiva coverage-clock article. The court's order:
- Stayed the appointments of the ACIP members named in 2025–2026 and enjoined HHS from treating the reconstituted committee as lawfully seated without the Federal Advisory Committee Act (FACA; 5 U.S.C. App. 2) procedures the court required.
- Barred the committee from convening or taking formal votes on immunization-schedule recommendations while the injunction remains in effect.
Because of this injunction, ACIP has been unable to hold formal voting sessions to adopt new schedule resolutions or formally recategorize existing vaccines.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ HHS RFI VS. ACIP ADJUDICATION: PROCEDURAL SEPARATION │
├───────────────────────────────────┬──────────────────────────────────────────────────────────┤
│ Administrative Layer │ Current Legal & Operating Status │
├───────────────────────────────────┼──────────────────────────────────────────────────────────┤
│ HHS Office of the Secretary │ • Active and moving forward under Docket HHS-OS-2026-0332│
│ (August 24 RFI) │ • Solicits public comment on policy concepts. │
│ │ • Cannot unilaterally rewrite 45 CFR 147.130 via RFI. │
├───────────────────────────────────┼──────────────────────────────────────────────────────────┤
│ ACIP Charter Committee │ • Operationally FROZEN under March 16, 2026 injunction. │
│ (FACA Advisory Body) │ • Cannot vote on new product resolutions or categories. │
│ │ • District court litigation pending on merits. │
├───────────────────────────────────┼──────────────────────────────────────────────────────────┤
│ Downstream Product Approvals │ • FDA BLA approvals continue normally. │
│ (e.g. mRNA Flu, Next-Gen RSV) │ • Coverage clocks cannot start until ACIP votes and CDC │
│ │ Director formally adopts schedule additions. │
└───────────────────────────────────┴──────────────────────────────────────────────────────────┘
The August 24 RFI is an HHS Office of the Secretary administrative inquiry, conducted under general departmental authority. It does not lift the AAP v. Kennedy injunction, does not convene ACIP, and does not alter existing CDC immunization schedules. Commercial sponsors tracking pipeline vaccines—such as the candidates surveyed in our mRNA vaccine pipeline census—must recognize that an HHS RFI cannot substitute for the formal ACIP resolution required to activate the statutory one-year ACA § 2713 coverage clock.
What Manufacturers, Payers, and State Programs Must File by September 20
With the public comment period closing on September 20, 2026, stakeholders across the healthcare economy must prepare targeted, evidence-based docket submissions rather than generic policy statements.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ STRATEGIC DOCKET PRIORITIES FOR SEPTEMBER 20, 2026 │
├─────────────────────────┬────────────────────────────────────────────────────────────────────┤
│ Stakeholder Group │ High-Priority Operational Submission Focus │
├─────────────────────────┼────────────────────────────────────────────────────────────────────┤
│ Vaccine Manufacturers │ • Demand explicit affirmation of 45 CFR 147.130 coverage │
│ │ equivalence for any new or modified recommendation category. │
│ │ • Highlight commercial launch risks if payers treat modified │
│ │ categories as elective, uncovered benefits. │
├─────────────────────────┼────────────────────────────────────────────────────────────────────┤
│ Commercial Payers & PBMs│ • Request standardized billing codes and clear operational │
│ │ guidance to prevent improper claims adjudication. │
│ │ • Clarify 12-month implementation grace periods under ACA § 2713 │
│ │ if schedule formats or category names are modified. │
├─────────────────────────┼────────────────────────────────────────────────────────────────────┤
│ State Medicaid & VFC │ • Detail the operational impossibility of bifurcating VFC ordering │
│ Coordinators │ if pediatric vaccines are split across new category tiers. │
│ │ • Warn against disruption to state school-entry immunization laws. │
├─────────────────────────┼────────────────────────────────────────────────────────────────────┤
│ Provider Organizations │ • Emphasize administrative burden and uncompensated counseling │
│ (AMA, AAP, AAFP) │ time if SCDM / individual-based requirements expand. │
│ │ • Advocate for dedicated CPT counseling reimbursement codes. │
└─────────────────────────┴────────────────────────────────────────────────────────────────────┘
1. Key Manufacturer Comment Priorities
Manufacturers must directly address Question 12, providing empirical data on how clearinghouses and commercial payers currently adjudicate SCDM claims. Submissions should urge HHS to issue explicit binding sub-regulatory guidance to private payers clarifying that 45 CFR 147.130 prohibits cost-sharing on any vaccine appearing on the CDC schedule, regardless of whether the category is designated as routine, risk-based, or shared decision-making.
2. Commercial Payer and Health Plan Priorities
Payers should highlight the operational complexity of verifying whether a "shared clinical decision" took place. If health plans are required to enforce zero cost-sharing without prior authorization, plans need clear billing modifiers to ensure that provider claims are processed correctly without administrative friction or retrospective audits.
3. State Public Health and VFC Coordinator Priorities
State immunization programs should focus on Question 6, demonstrating how existing state statutory codes tie school immunization requirements directly to "routine ACIP recommendations." Any sudden reclassification by the federal government risks creating immediate statutory voids in state public health laws.
Frequently Asked Questions
Does moving a vaccine from routine to shared clinical decision-making automatically end ACA no-cost-share coverage?
No. Under 45 CFR 147.130, non-grandfathered commercial group health plans and individual insurance policies must cover, with zero cost-sharing, all immunizations recommended by ACIP and adopted by the CDC Director that appear on the CDC immunization schedules. As HHS itself affirms in Question 12 of the August 24 RFI, SCDM recommendations that appear on the CDC schedule carry the same mandatory zero-cost-sharing protections as routine recommendations.
Is the August 24 HHS RFI a formal change to the child or adult immunization schedule?
No. The RFI is a Request for Information issued by the Office of the Secretary (Docket No. HHS-OS-2026-0332). It does not alter existing CDC immunization schedules, does not amend federal regulations at 45 CFR 147.130, and does not alter the clinical recommendations currently in effect.
When do public comments close, and where should they be submitted?
Comments must be received on or before September 20, 2026. Submissions must reference Docket No. HHS-OS-2026-0332 and RIN 0991-ZA62 and should be submitted electronically via the Federal eRulemaking Portal at Regulations.gov. The Federal Register notice states that date; it does not specify a clock time.
Does this RFI resolve the legal freeze on ACIP under AAP v. Kennedy?
No. The preliminary injunction issued on March 16, 2026 in AAP v. Kennedy remains in effect, barring the reconstituted ACIP from convening or voting on vaccine recommendations. The HHS RFI is an independent administrative proceeding by the Office of the Secretary and cannot bypass the federal court injunction.
Can a commercial health plan impose prior authorization on an SCDM vaccine?
While plans generally cannot impose cost-sharing (copayments, coinsurance, or deductibles) on schedule-listed ACIP immunizations under ACA § 2713, plans may utilize reasonable medical management techniques to ensure an individual falls within the recommended age or clinical cohort. However, imposing burdensome prior authorization that restricts access to schedule-listed immunizations is subject to strict regulatory scrutiny by HHS, Labor, and Treasury.
Sources
- U.S. Department of Health and Human Services. "Request for Information: Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making." Federal Register, Vol. 91, No. 163, August 24, 2026, pp. 54724–54728 (FR Doc. 2026-17250; Docket No. HHS-OS-2026-0332; RIN 0991-ZA62). Available at: FederalRegister.gov.
- U.S. Department of Health and Human Services. "HHS Seeks Public Input on Federal Vaccine Recommendation Categories and Shared Clinical Decision-Making." Press Release, Washington, D.C., August 21, 2026. Available at: HHS.gov Press Room.
- Centers for Disease Control and Prevention. "ACIP Shared Clinical Decision-Making Recommendations." Advisory Committee on Immunization Practices, Content current as of August 2026. Available at: CDC.gov ACIP.
- Electronic Code of Federal Regulations. "45 CFR § 147.130 — Coverage of preventive health services." Title 45, Subtitle A, Subchapter B, Part 147. Available at: eCFR.gov.
- U.S. District Court for the District of Massachusetts. American Academy of Pediatrics et al. v. Kennedy et al. Preliminary injunction described in this site's mFlusiva coverage-clock article, Civil Action No. 26-cv-10412, March 16, 2026. This RFI article relies on that prior site record for the injunction's existence and effect; it does not independently reproduce the PACER docket PDF.
- Centers for Medicare & Medicaid Services. "Vaccines for Children (VFC) Program Overview." Social Security Act § 1928 (42 U.S.C. § 1396s). Available at: Medicaid.gov.
- Center for Infectious Disease Research and Policy (CIDRAP). "How shared decision-making weakens vaccine policy." Commentary and Analysis, August 2026. Available at: CIDRAP.umn.edu.
